Fig. 3: Different decay kinetics of anti-Spike and anti-RBD IgG versus IgA in saliva from participants receiving COVID-19 mRNA vaccines. | Mucosal Immunology

Fig. 3: Different decay kinetics of anti-Spike and anti-RBD IgG versus IgA in saliva from participants receiving COVID-19 mRNA vaccines.

From: Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Fig. 3: Different decay kinetics of anti-Spike and anti-RBD IgG versus IgA in saliva from participants receiving COVID-19 mRNA vaccines.

Saliva from n = 32 LTCH participants was assessed for the presence of IgG (A, B), IgA (C, D), and SIgA (E, F) antibodies against Spike (A, C, E) or RBD (B, D, F). The Wilcoxon signed-rank test was used to calculate significance between groups. ns not significant, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page